As filed with the Securities and Exchange Commission on March 2, 2023
Registration No. 333-266893
Registration No. 333-253506
Registration No. 333-241680
Registration No. 333-182877
Registration No. 333-153167
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Post-Effective Amendment No. 1 to Form S-3, Registration Statement No. 333-266893
Post-Effective Amendment No. 1 to
Form S-3, Registration Statement No. 333-253506
Post-Effective Amendment No. 1 to Form S-3, Registration Statement No. 333-241680
Post-Effective Amendment No. 1 to
Form S-3, Registration Statement No. 333-182877
Post-Effective Amendment No. 1 to Form S-3, Registration Statement No. 333-153167
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Albireo Pharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
90-0136863
|
(State or other jurisdiction of incorporation) |
|
(IRS Employer Identification No.) |
53 State Street, 19th Floor
Boston, Massachusetts 02109
(Address, including zip code, of principal executive offices)
Registrants telephone number, including area code: (857) 254-5555
Ronald H.W. Cooper
Albireo Pharma, Inc.
53
State Street, 19th Floor
Boston, Massachusetts 02109
(857) 254-5555
(Name and address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
|
|
|
Tony Chan, Esq.
Orrick, Herrington & Sutcliffe LLP
Columbia Center 1152 15th
Street, N.W. Washington, DC 20005-1706 |
|
Niki Fang, Esq.
Lynne T. Hirata, Esq.
Orrick, Herrington & Sutcliffe LLP
405 Howard Street San
Francisco, CA 94105-2669 |
Approximate date of commencement of proposed sale to the public: Not applicable.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box: ☐
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to
Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that
shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If this form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or
additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large
accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.:
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐